CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Tofacitinib ointmentdrug
Likely dose
Tofacitinib ointment, frequency and concentration not specified; treatment duration maximum 6 monthsAI-extracted
Key inclusion· 4
  • ✓Diagnosis of alopecia areata with at least 2 patches on the scalp, alopecia totalis, or alopecia universalis
  • ✓Hair loss stable for 6 months or longer
  • ✓No alopecia treatment in the past 1 month
  • ✓No evidence of spontaneous hair regrowth
Key exclusion· 9
  • ✕Treatment for alopecia areata within 1 month of enrollment
  • ✕Current episode of alopecia totalis or universalis lasting more than 5 years
  • ✕History of malignancy, except successfully treated basal cell or squamous cell carcinoma of skin
  • ✕HIV, hepatitis B, or hepatitis C infection

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02812342
NCT02812342Phase 2Completed
CompareCT.gov

Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Yale University·interventional·Posted Jun 24, 2016·Updated Jan 30, 2019

In Brief

A Phase 2 clinical trial evaluating Tofacitinib ointment for Alopecia Areata and 2 related conditions. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of the study is to investigate the use of topical tofacitinib to promote hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata, Alopecia Totalis, Alopecia Universalis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 24, 2016
Enrollment StartSep 1, 2016
Primary CompletionJul 1, 2018
Study CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.0 years ago

Interventions

Tofacitinib ointmentdrug

Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.